Trex Wind Down Inc. (TMBRQ)
| Market Cap | 616.22 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.93M |
| Shares Out | 3.08M |
| EPS (ttm) | -3.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 806 |
| Open | n/a |
| Previous Close | 0.0002 |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TMBRQ
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclini... [Read more]
Financial Performance
In 2022, Trex Wind Down's revenue was $83,177, a decrease of -90.62% compared to the previous year's $886,532. Losses were -$19.38 million, 80.0% more than in 2021.
Financial StatementsNews
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
MADISON, N.J.--(BUSINESS WIRE)--Timber Pharmaceuticals, Inc., a LEO Pharma Comp., Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis CI.
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma today announced that it has finalized the acquisition of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals followin...
NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to immediately suspend trading in the common stock of ...
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercia...
NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of ...
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance
WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on ...
TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Timber Pharmaceu...
TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Timber Pharmaceuticals, Inc. (NYSE: TMBR) to LEO Pharma A/S is fair to Timber shareholder...
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals.
Timber Pharmaceuticals to be Acquired by LEO Pharma
WARREN, NJ, Aug. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR) today announced that it has entered into a definitive a...
Timber Pharmaceuticals Discloses Communication From NYSE American
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on t...
Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin -
Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled -
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results
- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber...
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results
- Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI -
Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology
- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary endpoints versus vehicle regardless of the subtype of congenital ichthyosis -
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany
Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook
Virtual Business Briefing With Q&A to be Webcast on December 20, 2022 at 10:30 am ET
Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
BASKING RIDGE, NJ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company fo...
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001-
Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split
BASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company focu...
Timber Pharmaceuticals Announces Halt of Common Stock Trading
Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split
Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis
- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application - - Company Plans to Submit Additional Application for Orphan Designation in Europe for TMB-001 for the Tr...
Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering
BASKING RIDGE, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focus...
Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis
European Commission expected to issue its decision on orphan designation in approximately 30 days